499 related articles for article (PubMed ID: 10470218)
21. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer.
Nisman B; Amir G; Lafair J; Heching N; Lyass O; Peretz T; Barak V
Anticancer Res; 1999; 19(4C):3549-52. PubMed ID: 10629651
[TBL] [Abstract][Full Text] [Related]
22. [Lung cancer].
Komagata H; Yoneda S
Gan To Kagaku Ryoho; 2004 Oct; 31(10):1609-13. PubMed ID: 15508459
[TBL] [Abstract][Full Text] [Related]
23. Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Philipp M; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Clin Exp Med; 2003 Feb; 2(4):185-91. PubMed ID: 12624710
[TBL] [Abstract][Full Text] [Related]
24. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E
Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
[TBL] [Abstract][Full Text] [Related]
25. [The diagnostic values of CA242 combining other tumor markers for lung cancer].
Zhang S; Ma Y; Yang X
Zhonghua Jie He He Hu Xi Za Zhi; 1999 May; 22(5):271-3. PubMed ID: 11775851
[TBL] [Abstract][Full Text] [Related]
26. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC).
Shibayama T; Ueoka H; Nishii K; Kiura K; Tabata M; Miyatake K; Kitajima T; Harada M
Lung Cancer; 2001 Apr; 32(1):61-9. PubMed ID: 11282430
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer.
Spinazzi A; Soresi E; Boffi R; Nonis A; Noseda A; Cobelli S; Scanni A
Cancer Detect Prev; 1994; 18(3):209-20. PubMed ID: 8076383
[TBL] [Abstract][Full Text] [Related]
28. [Neuron-specific enolase (NSE) and squamous cell carcinoma antigen (SCC) as serum markers in the diagnosis of bronchial carcinoma].
Lorenz J; Gillmann-Blum D; Jensen M; Kreienberg R
Pneumologie; 1990 Nov; 44(11):1259-63. PubMed ID: 2177891
[TBL] [Abstract][Full Text] [Related]
29. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
Ebert W; Hoppe M; Muley T; Drings P
Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552
[TBL] [Abstract][Full Text] [Related]
30. [Cyfra 21-1--a new tumor marker of the cytokeratin series in differential diagnosis of lung diseases].
Oremek GM; Seiffert UB; Siekmeier R; Kirsten R
Med Klin (Munich); 1995 Jan; 90(1):23-6. PubMed ID: 7533887
[TBL] [Abstract][Full Text] [Related]
31. Assessment of serum CYFRA 21-1 in lung cancer.
Muraki M; Tohda Y; Iwanaga T; Uejima H; Nagasaka Y; Nakajima S
Cancer; 1996 Apr; 77(7):1274-7. PubMed ID: 8608502
[TBL] [Abstract][Full Text] [Related]
32. Five tumor markers in lung cancer: significance of total and "lipid"-bound sialic acid.
Kakari S; Stringou E; Toumbis M; Ferderigos AS; Poulaki E; Chondros K; Dema A; Kotsovoulou V; Pavlidis N
Anticancer Res; 1991; 11(6):2107-10. PubMed ID: 1663720
[TBL] [Abstract][Full Text] [Related]
33. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
[TBL] [Abstract][Full Text] [Related]
34. [Clinical significance of tumor markers CYFRA 21-1 and neuron-specific enolase in lung cancer].
Kushlinskiĭ NE; Liubimova NV; Lemeshko AO; Vasil'ev AV; Davydov MI
Biull Eksp Biol Med; 1997 Jan; 123(1):98-100. PubMed ID: 9213472
[No Abstract] [Full Text] [Related]
35. Expression of CEA and trophoblastic cell markers by lung carcinoma in association with histological characteristics and serum marker levels.
Slodkowska J; Szturmowicz M; Rudzinski P; Giedronowicz D; Sakowicz A; Androsiuk W; Zakrzewska-Rowinska E
Eur J Cancer Prev; 1998 Feb; 7(1):51-60. PubMed ID: 9511851
[TBL] [Abstract][Full Text] [Related]
36. [Tumor markers in pleural effusion of patients with lung cancer and patients with tuberculous pleurisy].
Tada A; Kawai H; Matsumoto H; Kimura G; Okada C; Soda R; Takahashi K
Nihon Kokyuki Gakkai Zasshi; 2002 Feb; 40(2):106-12. PubMed ID: 11974864
[TBL] [Abstract][Full Text] [Related]
37. Clinical value of neuron specific enolase and tissue polipeptidic antigen for the management of patients with lung cancer.
Spinazzi A; Soresi E; Borghini U; Boffi R; Vigorelli R; Scoccia S
J Nucl Med Allied Sci; 1990; 34(4 Suppl):141-5. PubMed ID: 1965446
[No Abstract] [Full Text] [Related]
38. CYFRA 21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy.
Ebert W; Muley T
Anticancer Res; 1999; 19(4A):2669-72. PubMed ID: 10470217
[TBL] [Abstract][Full Text] [Related]
39. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].
Li R; Li R; Wang Y
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296
[TBL] [Abstract][Full Text] [Related]
40. Cut-off levels of NSE to differentiate SCLC from NSCLC.
Satoh H; Ishikawa H; Kurishima K; Yamashita YT; Ohtsuka M; Sekizawa K
Oncol Rep; 2002; 9(3):581-3. PubMed ID: 11956631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]